44-year-old male presents for check-up. Conditions: Type 2 diabetes,

Question

Accepted Answer

Next steps in management and investigations for this 44-year-old male with type 2 diabetes, hypothyroidism, hyperlipidaemia, essential hypertension, and stage 3 chronic kidney disease (CKD) include a comprehensive and individualized approach addressing glycaemic control, cardiovascular risk, renal function, and comorbidities.

First, confirm and optimize glycaemic control by reviewing HbA1c levels, aiming for individualized targets typically around 48 mmol/mol (6.5%) if managed with lifestyle or non-hypoglycaemic agents, or about 53 mmol/mol (7.0%) if hypoglycaemic therapies are used, tailoring targets based on the patient's preferences, risk of hypoglycaemia, and comorbidities ,. HbA1c should be measured every 3 to 6 months until stable, then at least every 6 months . Consider intensification of glucose-lowering therapy if control is suboptimal, while balancing risk of hypoglycaemia, especially given existing CKD, which limits certain agents , . Lifestyle advice on diet, physical activity, and weight management remains fundamental ,.

Given stage 3 CKD, regularly monitor kidney function via estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (ACR). If ACR is 3 mg/mmol or higher, begin or optimise treatment with an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), titrating to the highest tolerated dose to slow progression of diabetic nephropathy and reduce cardiovascular risk ,. For albuminuria above 30 mg/mmol with stable ACEi/ARB treatment and appropriate eGFR, consider adding an SGLT2 inhibitor if licensed and tolerated, as this class lowers progression of kidney disease and cardiovascular events . Monitor renal function and electrolytes after initiation or dose adjustment of these agents ,.

Because of essential hypertension and hyperlipidaemia, ensure target blood pressure (usually <140/90 mmHg, individualised) and lipid control are achieved, as these influence cardiovascular and renal outcomes . Investigate for target organ damage including haematuria, hypertensive retinopathy via fundoscopy, and left ventricular hypertrophy using ECG . Estimate 10-year cardiovascular risk (e.g., QRISK) and manage with statins per guidelines ,. Avoid antiplatelet therapy unless established cardiovascular disease is present .

Screen routinely for diabetes complications such as diabetic retinopathy, neuropathy (including autonomic neuropathy affecting bladder or gastrointestinal symptoms), and foot problems with appropriate multidisciplinary referrals as indicated ,. Assess for psychosocial issues and provide support .

Review and monitor thyroid function given hypothyroidism, as this may impact cardiovascular risk and glycaemic control . Ensure hypothyroidism is optimally managed.

Continue routine monitoring of lipid profiles and electrolytes . Advise on vaccinations, including influenza and pneumococcal vaccines, to reduce infection risks .

Investigations should include repeat HbA1c, renal function tests (eGFR, creatinine), urine ACR, lipid profile, blood pressure measurement, thyroid function, fundoscopy, ECG, and foot examination ,,,.

Additionally, literature reinforces the importance of early and individualized treatment intensification to improve glycaemic control while minimising hypoglycaemia, which can affect quality of life and outcomes . Polypharmacy risks should be reviewed carefully, optimising medications to reduce adverse effects and drug interactions .

In summary, management involves comprehensive risk factor control, regular monitoring of diabetes and CKD progression, individualised therapy adjustments, complication screening, and psychosocial support to improve overall outcomes in this patient ,,, .

44-year-old male presents for check-up. Conditions: Type 2 diabetes,

Key References

Related Knowledge Topics